Velox Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Velox Therapeutics, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ABATA. The owner is based in Boston, MA.
29 Newbury St., 3rd Floor
Boston, MA 02116
Showing of trademarks Trademarks
Trademark Classifications
Velox Therapeutics, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Velox Therapeutics, Inc. have?
Velox Therapeutics, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned.
What trademark classes does Velox Therapeutics, Inc. file in?
Velox Therapeutics, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Velox Therapeutics, Inc.'s most well-known trademarks?
Velox Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as ABATA. These are among 1 currently registered trademark in the portfolio.
What is Velox Therapeutics, Inc.'s trademark registration success rate?
Velox Therapeutics, Inc. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.